Skip to content

Oxidative Stress and L-CBMN Cytome Assay in Obese After 3 Weeks VLCD

Oxidative Stress and L-CBMN Cytome Assay Parameters Levels in Severely Obese With BMI ≥ 35kg/m2 After 3 Weeks 567 kcal Hospital Controlled VLCD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05055154
Enrollment
26
Registered
2021-09-24
Start date
2019-06-14
Completion date
2020-11-03
Last updated
2021-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Weight Loss, DNA Damage

Keywords

Obesity, Very low calorie diet, Oxidative stress, Micronuclei, apoptosis

Brief summary

Obesity leads to physiological imbalance resulting in hyperglycemia, dyslipidaemia and inflammation and can generate systematic oxidative stress through multiple biochemical mechanisms. Oxidative stress (OS) can induce DNA damage and inhibit DNA repair mechanisms. Very low calorie diet (VLCD) have rapid positive effect on weight loss, glucose homeostasis, insulin resistance, inflammation and OS. The aim of this study is to determine the effect of a three-week VLCD on anthropometric, biochemical and genomic parameters in individuals with BMI ≥ 35kg/m2.

Detailed description

Obesity is a complex chronic multifactorial disease associated with concomitant or increased risk for chronic inflammation, insulin resistance, dyslipidemia, oxidative stress, type 2 diabetes, cardiovascular disease, stroke and multiple cancer types. Oxidative stress (OS) can cause permanent DNA damage which could be detected with lymphocytes cytokinesis-block micronucleus (L-CBMN) cytome assay. Weight loss and improvement of dietary habits in people with obesity can affect genome stability and have beneficial effects on insulin sensitivity, inflammation and OS. Effects of very low calorie diet (VLCD) on DNA damage are scarce. The aim of this study is to determine the effect of a three-week VLCD used in Special Hospital for extended treatment of Duga Resa in patients with BMI ≥ 35kg/m2 on permanent DNA damage, lipid profile, insulin resistance, inflammation and anthropometric parameters.

Interventions

In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks

Sponsors

Institute for Medical Research and Occupational Health
CollaboratorUNKNOWN
University of Zagreb
CollaboratorOTHER
Special Hospital for Extended Treatment of Duga Resa
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* body mass index ≥ 35 kg/m2

Exclusion criteria

* pregnancy * actual tumor diseases * recent diagnostic or treatment exposures to ionizing radiation in the period of one year * individuals not willing to stay 3 weeks under supervision under full 24 h surveillance from the medical stuff

Design outcomes

Primary

MeasureTime frameDescription
The changes in inflammation parametersBaseline, after 3 weeks of VLCDConcentration of C-reactive protein (mg/L) and total white blood cell count
The changes in insulin concentrationBaseline, after 3 weeks of VLCDConcentration of insulin (mIU/L)
The changes in homeostatic model assessment (HOMA) indexBaseline, after 3 weeks of VLCDHOMA index is calculated according to the following formula: glucose (mmol/L) x insulin (mIU/L)/22.5
The changes in body mass indexBaseline, after 3 weeks of VLCDBody mass index is calculated by dividing body mass (kg) with square of body height (m)
The changes in the body fat massBaseline, after 3 weeks of VLCDBody fat mass (kg) assessed with bioelectrical impedance method
The changes in the skeletal muscle massBaseline, after 3 weeks of VLCDSkeletal muscle mass (kg) assessed with bioelectrical impedance method
The changes in the percent body fatBaseline, after 3 weeks of VLCDPercent body fat (%) assessed with bioelectrical impedance method
The changes in fasting glucose concentrationBaseline, after 3 weeks of VLCDConcentration of glucose (mmol/L)
The changes in urea concentrationBaseline, after 3 weeks of VLCDConcentration of urea (mmol/L)
The changes in lipid profileBaseline, after 3 weeks of VLCDConcentrations of triglycerides (mmo/L), LDL (mmol/L), HDL (mmol/L) cholesterol (mmol/L)

Secondary

MeasureTime frameDescription
The changes in DNA damageBaseline, after 3 weeks of VLCDFrequency of micronucleus, nuclear buds, nucleoplasmic bridges, apoptotic and necrotic cells among 1000 lymphocytes
The changes in oxidative stressBaseline, after 3 weeks of VLCDConcentration of glutathione (RFU) and reactive oxygen species (RFU)

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026